The serum concentration of valproic acid (VPA) in epilepsy patients decreased by the administration of carbapenem antibiotics, such as meropenem, panipenem or imipenem, to a sub-therapeutic level. Studies to explain the decrease were carried out using almost rats by the following steps: absorption of VPA in the intestine, glucuronidation in the liver, disposition in blood and renal excretion. It is difficult to consider the inhibition of intestinal absorption, because carbapenem antibiotics are intravenously administered and do not reach the intestine at an effective concentration. The liver is the key organ for the decrease of VPA concentration by carbapenem antibiotics, because it has been reported that no decrease of the VPA level by carbapenem was found in hepatectomized rats. The most likely mechanism in liver is the activation of UDP-glucuronosyltransferase by carbapenem antibiotics. We found a 35% increase of VPA-glucuronidation activity by the pre-incubation of human liver microsomes with meropenem. We estimated that this increase fully compensates for the decrease of serum VPA level by carbapenem antibiotics in patients. Meanwhile, we could not find the in vitro activation of CYP2A6, CYP3A4, P-glycoprotein (P-gp, MDR1) and Multidrug resistance-associated protein 2 by pre-incubation with carbapenem antibiotics. Thus, we considered that the activation of VPA glucuronidation by carbapenem antibiotics is a key point in the decrease of plasma VPA level.
INTRODUCTION
Most xenobiotics, such as drugs, non-nutrient chemicals in foods, and pollutants are metabolized in the human body. 1) Phase I drug-metabolizing enzymes functionalize lipophilic drugs by adding active residues such as OH to the drugs. Phase II metabolizing enzymes conjugate with watersoluble substances, such as uridine 5 -diphosphate (UDP)-glucuronic acid (UDPGA) for UDPglucuronosyltransferase (UGT), 2, 3) PAPS for sulfotransferase, 4) and glutathione for glutathione S-transferase, to further functionalize the drugs. These soluble conjugates are excreted in the bile and the urine by transporters. 5) Drug-drug interactions are reported in patients administered several * To whom correspondence should be addressed: Department of Drug Metabolism and Disposition, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya 467-8603 Japan.
Tel.&Fax: +81-52-836-3490; E-mail: mizutani@phar.nagoya-cu.ac.jp drugs. A typical example is the transcriptional induction of CYP3A4 by rifampicin. Ethinylestradiol used for contraception was rapidly metabolized by a high amount of CYP3A4 induced by rifampicin, and unexpected pregnancy occured. 6) In addition to transcriptional gene activation of drug-metabolizing enzymes, molecular mechanisms of activation by stabilization, such as mRNA stabilization (CYP1A2 by 3-methylcholanthrene) and protein stabilization (CYP2E1 by ethanol, in part) and/or the increase of enzymes and/or cofactors supporting drug-metabolizing enzymes were found. However, there are drug-drug interactions, which are difficult to explain by the mechanisms described above. One is that the serum valproic acid (VPA) level in epilepsy patients decreases by the administration of carbapenem antibiotics (CPs), such as meropenem (MEPM), panipenem (PAPM), imipenem (IPM) and biapenem (BIPM). This decrease does not depend upon the transcriptional gene activation of some drug-metabolizing enzymes.
A decade ago, the plasma level of VPA (1-4 g dose) in an epilepsy patient rapidly decreased by the administration of panipenem, a carbapenem antibiotic, which was used to treat pneumonia and this decrease resulted in clinical failure. 7) VPA is excreted from the kidney after conjugation with glucuronide by UGT in the liver. In blood, VPA is the bound state with plasma protein and carbapenem antibiotics are not bound with plasma protein. The structure of VPA, capbapenem antibiotics, and related other drugs used in therapy of epileptic patients or this study are shown in Fig. 1 .
The main purpose of this study is to clarify the mechanism of the decrease of VPA level in blood by carbapenem antibiotics. Studies to explain the decrease were carried out using almost rats by the following steps (Table 1) : [8] [9] [10] [11] [12] [13] [14] [15] absorption of VPA in the intestine, glucuronidation in the liver, disposition in blood and renal excretion. In the intestine of absorption step, there are two points: inhibition of the intestinal transporter for VPA absorption 
MATERIALS AND METHODS
Materials --Pooled human liver microsomes (HLM) and P-glycoprotain (P-gp, MDR1) are purchased from Gentest (Woburn, MA, U.S.A.). Human MRP2 membranes were a gift from Genomembrane (Yokohama, Japan).
P-gp and MRP2 are products prepared in Sf9 cell membrane using a baculovirus expression system. Bovine microsomes and murine microsomes were prepared by the standard method. 16 16) HLM not activated in TritonX-100 was used except experiments described the addition of Triton X-100. HLM (1 µl) was pre-incubated at 0 • C or 37 • C for 30 min in a mixture (49 µl) composed of 20 mM Tris-maleate (pH 7.4), 1 mM MgCl 2 , 2 mM [ 14 C]UDPGA (2 µCi) and MEPM at appropriate concentration. The reaction was started by addition of 1 µl of 100 mM VPA (final concentration 2 mM) and incubated for The influences of MEPM for glucuronidation of p-NP and androsterone, instead of VPA, were carried out according to the same method of VPA glucuronidation. The glucuronidation products with p-NP and androsterone were also analyzed by the same method described above. The influence of streptomycin and ampicillin instead of MEPM on VPA glucuronidation was also studied as described above. Measurement of the Activity of Transporters --The activity of P-gp was determined by the measurement of inorganic phosphate liberator from ATP. We used the radioactive [γ-32 P]ATP for the measurement of inorganic phosphate. This method is different from the method with the standard phospho-morybdate method. 17) Our method is based on the fact that [γ-32 P]ATP absorbs on charcoal and inorganic phosphate does not adsorb on charcoal. 18) [γ-32 P]ATP of a product from a maker was used further purification. We analyzed the product [γ-32 P]ATP by chromatography on a column of AG1 (BioRad). The reaction mixture (19 µl) containing P-gp (1 µl, 5 µg) or MRP2 (5 µl, 100 µg) in 50 mM Tris-MES, 2 mM EGTA, 1 mM [ 32 P]ATP (0.2 µCi), 50 mM KCl, 2 mM DTT were pre-incubated with MEPM at appropriate concentration for 30 min at 0 • C. The reaction was started by addition of 1 µl of verapamil, VPA or VPA-Glu. The incubation was done for 30 min at 37 • C. The reaction was stopped by addition of 40 µl of 10% charcoal (Norit A) in 0.1 M phosphate buffer, followed by centrifugation at 8000 rpm. Charcoal binding ATP was removed by this centrifugation and the supernatant containing 32 P inorganic phosphate was applied to a filter paper and dried. The radioactivity of 32 P on the filter paper was analyzed using the radio-image analyzer Fuji BAS 2500. Measurement of the Activity of Cytochrome P450 --The influence of carbapenem antibiotics on CYP2A6 and CYP3A4 were studied with HLM and bovine liver microsomes. The activity of CYP2A6 was measured by the previous report. 19, 20) HLM (4 µg) was preincubated with MEPM in 15 µl at 0 • C for 30 min. The reaction was started by addition of the reaction mixture (15 µl) composed of 3 mM MgCl 2 , 1.3mM NADP + , 3.3 mM glucose-6-phosphate, 0.4 U glucose-6-phosphate dehydrogenase, 10 mM coumarin and 0.1 M Tris-HCl (pH 7.4). The mixture was incubated for 30 min at 37 • C and the reaction was stopped by addition of 70 µl of cold ethanol. The solution was centrifuged and the supernatant was mixed with 700 µl of 0.1 M Tris-HCl (pH 9) and the mixture 200 µl was measured by ARVO 1400 by fluorometry in triplicate. The amount of the product 7-hydroxycoumarin from coumarin was measured with ALVO 1400. The activity of CYP3A4 was measured with an assay kit for CYP3A4, by the similar method with that of CYP2A6, except 7-benzyloxytrifluoromethylcoumarin (67 µM) was used instead of coumarin.
Fluorometry was done excitation 409 nm and emission 530 nm for CYP3A4, and excitation 399 nm and emission 460 nm for CYP2A6. 7-Hydroxytrifluoromethylcoumarin was used as a standard of product with CYP3A4. Statistical Analyses --Experiment was done the sample number n = 5-6 of each point. Statistical significance was calculated by Student's t-test and * indicates p < 0.05. Each point indicates the mean ± S.D.
RESULTS

In Vitro Activation of VPA-glucuronidation by Carbapenem Antibiotics
We investigated the influence of preincubation with MEPM and BIPM. In preliminary experiments, we studied the influence at several concentrations. 12 µM or 120 µM MEPM and 20 µM or 200 µM BIPM at 0 • C or 37 • C. MEPM and BIPM did not activate UGT at high concentration at 37 • C, but at low concentration at 0 • C (about 40% increase of UGT activity without drugs) as shown in Fig. 2 . The concentration of these bands of VPA-Glu in lanes 1, 3, 5, 7 at 37 • C were low but those of lanes 2, 4, 6, 8 at 0 • C were strong in Fig. 2 . The density of lane 2 of 12 µM MEPM was higher than that of lane 4 of 120 µM MEPM. These concentrations 12 µM MEPM and 20 µM BIPM are near the in vivo concentrations of those drugs by therapeutic dose.
We then confirmed the above experiments with sample number 6 and the results are shown in Fig. 3 . We studied the influence with carbapenem antibiotics, such as MEPM, PAPM, IPN and BIPM. The preincubation was done at 0 • C for 30 min according to the results in Fig. 2 and then the reaction started by addition of VPA, like the above [16] . There were 6 samples in the experiment. Each points indicate the mean ± SD and statistical significance was calculated by Student's t-test. experiment with MEPM. The activities of VPA glucuronidation were increased to 134±20.4% at 12 µM MEPM, 122.6±16.0% at 15 µM PAPM, 118.3±8.1% at 16 µM IPM and 119.2±14.5% at 20 µM BIPM, compared to the activity as 100% in the absence of carbapenem antibiotics. The significant increase of the activity with MEPM was confirmed by the repeated experiments (data not shown). The increase (35%) of the activation by MEPM was slightly stronger than those of PAPM, IPM and BIPM. The Vmax value of VPA for UGT1A6 obtained by us is 2.5 nmol/min/mg of human liver microsomal protein. The amount of microsomal protein in the liver (1000 g) is approximately 100 g. The amount of VPA-Glu produced by the liver for 60 min was 2.5 nmol × 60 min × 100000 mg = 15 mmol. This 15 mmol VPA is 2500 mg. The 35% increase of UGT activity corresponds to about 875 mg (2500 mg × 0.35) for 1 hr. The therapeutic amount of administration of VPA is 400-1200 mg/day and this amount is able to be glucuronized by the 35% increase of UGT activity. Thus, the 20-35% activation of VPA conjugation by carbapenem antibiotics in Fig. 3 fully explained the decrease of serum VPA concentration and must influence on total clearance of VPA.
We also confirmed dose-dependency of the in Fig. 4 . Dose Dependency of the Activation of VPA Glucuronidation by MEPM Experimental conditions are the same in Fig. 3 . The MEPM concentrations used were 1.2 , 12, and 120 µM. vitro activation by MEPM as shown in Fig. 4 . MEPM activated at 12 µM and 120 µM and not activated at 1.2 µM. The concentration 12 µM was near the therapeutic level estimated from therapeutic dose in patients. Thus, it is possible that carbapenem antibiotics activate the activity of UGT1A6 in human liver to produce VPA-Glu, which is excreted from urine. We studied the activation of other ligands, such as p-NP and androsterone by MEPM. Table 2 shows that glucuronidation of p-NP by UGT1A6 and androsterone by UGT2B7 are increased by activation by preincubation in 12 µM MEPM to 132.7% and 116.1%, respectively. Thus, MEPM activates UGT2B7 as well as UGT1A6. It is possible that this activation is dependent on the phenomenon like the activation of Triton X-100. Therefore, we examined the influence on VPA glucuronidation by Triton X-100. The results were shown in Table 2 . At 0.025% Triton X-100, UGT was activated and the activity was the same level in the presence or absence of MEPM, 2.349±0.098 or 2.328±0.016 nmol/min/mg protein, respectively. Activation level by Triton X-100 was approximately 2-fold and the activation level by MEPM was about 1.3-fold. We could not find the additional effect by MEPM to the activation by Triton X-100. Thus, we thought that the mechanism of activation by MEPM differed from detergent property by Triton X-100.
Next, we studied the influence of other antibiotics, such as streptomycin and ampicillin, in VPA glucuronidation. In the presence of at 28 µM streptomycin, the activity of VPA glucuronidation was 1.182±0.047 nmol/min/mg protein, compared to the value of 1.329±0.086 nmol/min/mg protein in the absence of streptomycin. Meanwhile, in the presence of 27 µM ampicillin, the activity was 1.148±0.073 nmol/min/mg protein, different from the value 0.986±0.068 nmol/min/mg protein in the absence of ampicillin. This difference (16%) is small but significant between them. 
No Activation of P-gp and MRP2 by MEPM
We studied the influence of MEPM on the P-gp activity. The main purpose of this study is to clarify the mechanism for carbapenem antibiotics to decrease the level of serum VPA and we investigated in vitro transporting activity of VPA and VPA-Glu by P-gp. However, we could not detect any activity for VPA and VPA-Glu as substrates of P-gp, as shown in Table 3 . The ATPase activity of Pgp at 33 µM and 1.67 mM VPA was 31.97±1.019 and 30.59±2.110 nmol/min/mg protein, respectively, and these values are the same value of minus substrates 33.78±0.237 nmol/min/mg protein.
VPA-Glu also did not show any ATPase activity as substrates for P-gp, of those values 31.26-34.23 nmol/min/mg, with the same value of minus substrates. Thus, we could not detect the substrate activity of VPA and VPA-Glu for P-gp. As a matter of course, MEPM at 12 µM also showed no activation of P-gp. Thus, we could not study the influence of MEPM on the activity of P-gp for transport of VPA and VPA-Glu.
We studied the transporting activity of VPAGlu by MRP2. MRP2 did not show any transporting activity of VPA-Glu as shown in Fig. 5 . ATPase activity of VPA-Glu as substrates by MRP2 in the presence (3.855±0.019 nmol/min/mg protein) of 12 µM MEPM is the same value with that of absence of MEPM (3.930±0.063 nmol/min/mg protein), as shown in lanes 1 (−MEPM) and 2 (+MEPM). This indicates that MEPM did not activate the MRP2 activity on membranes. The activity of MRP2 membranes is slightly more than the ATPase activity of control membranes. MRP2 membranes show ATPase activity by probenecid of a specific substrate for MRP2.
We measured (ATP-binding cassette ABC) transporting activity in HLM, which might contain all membranous activities. The results are shown in Fig. 6 . We can detect slightly increase of ATPase activity in the presence of MEPM (4.35 nmol/min/mg protein). However, HLM contained high level of ATPase (55-57 nmol/min/mg protein) and we conclude no influence of MEPM on the transporters. We also studied with some ATPase inhibitors, such as EGTA and nitrilotriacetic acid, but it was difficult to see clear results. Recently, it has been reported that MRP4/5 plays a role of transport of VPA-Glu. 14) Thus, it is necessary to investigate with MRP4/5, although the experiment with the nephrectomized rats shows that kidney is not key organ for the decrease of serum VPA. Study of the influence of MEPM and the activity of CYP2A6 and CYP3A4. We studied the effect of MEPM on CYP activities with HLM, but we could not find any difference between presence and absence of MEPM as shown in Table 4 . We used the identical enzymes in the HLM for the measurement of activity of UGT and CYP. Cytochrome P450 in HLM was not activated by MEPM but UGT1A6 in HLM was activated by MEPM. We also confirmed no activation by MEPM with bovine liver microsomes. The specific activity of CYP2A6 was 0.292, 0.287 and 0.283 nmol/min/nmol CYP in the absence, 30 µM and 60 µM MEPM, respectively. Thus, we concluded that MEPM did not influence on the CYP activity.
DISCUSSION
In order to understand the mechanisms of serum VPA decrease by carbapenem antibiotics, many research as shown in Table 1 was carried out in vivo with rats. Our biochemical experiment was carried out in vitro with human liver microsomes. This biochemical study will become strong skill for future study of the mechanisms of drug interaction. Our results might coincident with the phenomenon in a patient. The activation of VPA glucuronidation by MEPM was not found at 37 • C but at 0 • C. We thought the protein conformation of UGT at 0 • C with MEPM might be maintained in the stable state. It is possible that the in vitro activation by carbapenem antibiotics may occur in patients. In our study, the used concentration of VPA and MEPM is the same or lower than the therapeutic level of those drugs. Thus, we believe that the activity increase of VPA glucuronidation by MEPM must occur in liver of patients.
Carbapenem antibiotics were used for the treatment of pneumonia when epileptic patients infected. MEPM has weak renal toxicity but IPM and PAPM have strong renal toxicity by hydrolyze with renal dehydroxypeptidase. Therefore, the enzyme inhibitiors such as cilastatin and betamipron were co-administered with IPM and PAPM, respectively. Thus, MEPM may be better in carbapenem antibiotics. The β-lactam antibiotics, such as imipenem and meropenem at 200-400 mg/kg, have convulsive activity, as well as epilepsy diagnosis, and this depends upon the binding of carbapenem to γ-amino-butyric acid (GABA) receptor. 21) Perucca reported some interactions between anti-epileptic drugs, such as carbamazepine, phenytoin, phenobarbital, and primidone. 22) These drugs induce some drug-metabolizing enzymes and decrease the plasma level of these drugs. VPA inhibited phenobarbital and lamotrigine. Co-administration of antiepileptic drugs caused a neurotoxic effect. VPA induced hyperammonemia and thrombocytopenia in an elderly woman and caused the inhibition of carbamoyl-phosphate synthase. 23) From interactions between anti-epileptic and anti-psychotic drugs, chlorpromazine of an anti-psychotic drug possibly increases VPA concentration. 24) The serum valproic acid (dose of VPA, 400-1200 mg/day) in epilepsy patients decreased by the administration of carbapenem antibiotics, such as meropenem, panipenem and imipenem. We surveyed the possible mechanisms explaining the decrease of the VPA level by carbapenem antibiotics as shown in Table 1 . Studies to explain the mechanism were carried out by the following steps, such as absorption of VPA in the intestine, glucuronidation in the liver, disposition in blood and renal excretion. It is difficult to consider the inhibition of intestinal absorption, because carbapenem antibiotics are intravenously administered and do not reach the intestine at an effective concentration. The liver is the key organ for the decrease of VPA concentration by carbapenem antibiotics, because no decrease of the VPA level by carbapenem was found in hepatectomized rats but was found in nephrectomized rats. Yamamura et al. 11) showed that panipenem increased the level of hepatic UDPGA in rats. It is well known that UDPGA is made from UDPglucose by UDP-glucose dehydrogenase. UDPglucose is a house keeping substance like blood glucose and a main component in the root of glucose metabolism between glycogen and the TCA cycle. UDPGA is abundant and the concentration is some mM; thus, it is difficult for us to agree with the changes of UDPGA concentration. Nakajima et al. 12) reported the mechanism of drug interaction between VPA and carbapenem antibiotics in monkeys and rats. UDPGA did not increase in monkey liver slices in the presence of carbapenem antibiotics. The most likely mechanism in liver is the activation of UGT by carbapenem antibiotics. We showed a 35% increase of VPA-glucuronidation activity by the pre-incubation of human liver microsomes with meropenem. This increase fully compensates for the decrease of serum VPA level by carbapenem antibiotics. VPA-Glu is easily excreted from the kidney. Thus, we considered that the activation of VPA glucuronidation by carbapenem antibiotics is a key reaction.
VPA was not a ligand of P-gp. We considered that the decrease of VPA depends on the renal excretion of VPA-Glu and P-gp might play a role in this excretion. 25) We could not find for VPA-Glu to be a ligand of P-gp and MRP2 also did not show the ATPase activity, However, we found a little activity with HLM which contains high ATPase activity, therefore some other trasnporters, not P-gp or MRP2, may function to excrete VPA-Glu from kidney. Recently, it has been reported Mrp4/5 have a function to export VPA-Glu from erythrocytes. 14) Thus, it is possible that MRP4 may function to excrete VPA-Glu from kidney. However, transporters in kidney is not a key role to decrease serum VPA level, because nephrectomized rat has the function to decrease serum VPA and this suggests that kidney is not a target organ of the decrease VPA level by carbapenem antibiotics.
The pre-incubation of HLM with MEPM did not increase on the activities of CYP2A6 and CYP3A4, which present on microsomal membranes with UGT. UGT1A6 catalyzes glucuronidation of VPA and p-NP. MEPM activates glucuronidation of VPA and p-NP depending on UGT1A6. MEPM also activates glucuronidation of androsterone by UGT2B7. Thus, MEPM did not activate cytochrome P450 but UGT. Meanwhile, this work did not clarify the specific activation of VPA by carbapenem antibiotics, because the activation by MEPM was found not only on UGT1A6 (VPA and p-NP) but also on UGT2B7 (androsterone) as shown in Table 2 . Perucca 22) and Besag et al. 24) described many interactions between antiepileptic and antipsychotic drugs. We found no activation of UGT1A6 by streptopmycin but found weak activity increase by ampicillin. Meanwhile, in clinical case reports, 7, 25) ampicillin and cephalosporin amtoniotics did not influence on plasma VPA level. These three antibiotics (carbapenem, penicillin, and cephalosporin) have similar structure as shown in Fig. 1 , but carbapenem antibiotics among three antibiotics have the decreasing activity of serum VPA level. The mechanism of activation of UGT by MEPM is not clarified but it is possible that MEPM at therapeutic concentration activates directly UGT molecules by chaperon-like activity or indirectly by stabilization change in membrane structure. The mechanism of the activity increase of glucuronidation will be studied in our future plan.
